Evidence map›Paper›PMID 11073832›Full record

ArticleThe American journal of pathology2000

Neutrophil priming by cigarette smoke condensate and a tobacco anti-idiotypic antibody.

S M Koethe, J R Kuhnmuench, C G Becker

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Review
  3. Unravelling the mechanisms driving multimorbidity in COPD to develop holistic approaches to patient-centred care.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2010
    Review
  18. Article
  19. Molecular pathogenesis of emphysema.The Journal of clinical investigation · 2008
    Review
  20. Future therapeutic treatment of COPD: struggle between oxidants and cytokines.International journal of chronic obstructive pulmonary disease · 2007
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

S M KoetheDepartment of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA. skoethe@mcw.edu
J R Kuhnmuench
C G Becker
Medical College of Wisconsin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A polyphenol-rich reagent, referred to as CSC, was isolated from cigarette smoke condensate and shown to prime purified human neutrophils. A mouse monoclonal anti-idiotypic antibody directed against the polyphenol-reactive determinants on a rabbit polyclonal anti-tobacco glycoprotein antibody was generated and shown to also prime neutrophils. After priming by CSC or tobacco anti-idiotypic antibody, there was a 2.5-fold to threefold increase in CD11b/18 expression and doubling of the number of formyl-methionyl-leucyl-phenylalanine receptors on the cells. The primed cells showed a twofold increase, compared with unprimed cells, in production of superoxide and release of neutrophil elastase after stimulation with formyl-methionyl-leucyl-phenylalanine. Neutrophils in peripheral blood of cigarette smokers have been shown to be primed and more responsive to activating agents. The priming effects attributed to whole cigarette smoke have been demonstrated in these studies using purified neutrophils and CSC or tobacco anti-idiotypic antibody. These studies are a first step in testing the hypothesis that the inflammatory process contributing to progression of chronic obstructive pulmonary disease in ex-smokers may be driven, in part, by tobacco anti-idiotypic antibodies. This hypothesis is novel and carries with it the implication of a heretofore unrecognized autoimmune component in the disease process manifested through production of anti-idiotypic antibodies with tobacco-like activity.

Indexed as

SmokeAntibodies, MonoclonalEnzyme ActivationEnzyme InhibitorsHumansImidazolesImmunoglobulin IdiotypesLeukocyte ElastaseMacrophage-1 AntigenMitogen-Activated Protein KinasesNeutrophilsN-Formylmethionine Leucyl-Phenylalaninep38 Mitogen-Activated Protein KinasesPhosphorylationPyridinesReceptors, Formyl PeptideAntibodies, MonoclonalEnzyme InhibitorsImidazolesImmunoglobulin IdiotypesLeukocyte ElastaseMacrophage-1 AntigenMitogen-Activated Protein KinasesN-Formylmethionine Leucyl-Phenylalaninep38 Mitogen-Activated Protein KinasesPyridinesReceptors, Formyl PeptideReceptors, ImmunologicReceptors, PeptideSB 203580Serum AlbuminSmokeSuperoxides

Identifiers

PMID11073832
PMCPMC1885717
OpenAlexW1967249754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.